Objective: Granisetron, GRA an adenosine receptor agonist with fewer side effects, could be of interest to reduce neuropathic pain following antineoplasic drug treatment. In the present study, we demonstrated that Granisetron inhibits hyperalgesia and allodynia in a new mice model of neuropathy induced by Vincristine, and exerts its effect preferentially via supraspinal and spinal mechanisms. M...

BACKGROUND The purpose of this study is to examine the risk of uncontrolled chemotherapy-induced nausea and vomiting (CINV) among patients receiving low emetogenic chemotherapy (LEC) with and without granisetron injection as the primary prophylaxis in addition to dexamethasone and metochlopramide. MATERIALS AND METHODS This was a single-centre, prospective cohort study. A total of 96 patients...

from general and regional anesthesia. the incidence of this complication is reported to be 40-70% among patients. pas occurrence depends on various factors such as age, gender and drugs used in anesthesia and surgery time. granisetron is a serotonin 5ht3 receptor antagonist. beneficial effects of such drugs have been shown in a limited number of studies. in this study, preventive effects of gra...

PURPOSE: To compare the efficacy and safety of oral ondansetron with i.v. granisetron each given as a single dose prior to administration of highly emetogenic cisplatin chemotherapy. PATIENTS AND METHODS: Chemotherapy-naive patients with histologically confirmed malignancies were randomized to receive a single 24 mg ondansetron hydrochloride tablet plus a 50 ml i.v. infusion of normal saline, o...

Topal A. , M. Kaya, N. Gül: Ondansetron and Granisetron in the Prophylaxis of Nausea and Emesis Induced by Cisplatin in Dogs. Acta Vet. Brno 2005, 74: 111-116. In the present study, the effects of 5-HT3 receptor antagonist granisetron and ondansetron on the acute phase of cisplatin-induced nausea and emesis were analyzed in dogs. Fifteen healty dogs were used in this study. Cisplatin was admini...

Background: Posotoprative nausea and vomiting remains a persistent and distressing problem inspite of many advances on perioperative care and anti-emetic drugs. A newer antiemetic drug Granisetron has not been studied in patients undergoing gynaecological surgery under spinal anaesthesia. Objective: A randomized double blind study was conducted to compare Ondansetron and Granisetron for prevent...

BACKGROUND 5-HT3-receptor antagonists are one of the mainstays of antiemetic treatment, and they are administered either i.v. or orally. Nevertheless, sometimes neither administration route is feasible, such as in patients unable to admit oral intake managed in an outpatient setting. Our objective was to evaluate the bioavailability of s.c. granisetron. PATIENTS AND METHODS Patients receiving...

1. Del Giglio A, Soares HP, Caparroz C et al. Granisetron is equivalent to ondansetron for prophylaxis of chemotherapy-induced nausea and vomit. Results of a meta-analysis of randomised controlled trials. Cancer 2000; 89: 2301–2308. 2. Grunberg SM. Phase I and other dose-ranging studies of granisetron. Semin Oncol 1992; 19 (Suppl 10): 16–22. 3. Perez EA, Hesketh P, Sandbach J et al. Comparison ...

BACKGROUND Postoperative nausea and vomiting (PONV) are frequently encountered after thyroidectomy. For PONV prevention, selective serotonin 5-hydroxytryptamine type 3 (5-HT3) receptor antagonists are considered one of the first-line therapy. We report on the efficiency of granisetron and tropisetron, with that of placebo on the prevention of PONV in patients undergoing total thyroidectomy. M...

OBJECTIVE To evaluate the efficacy of intravenous ramosetron plus dexamethasone for the prevention of acute chemotherapy-induced nausea and vomiting. METHODS Cancer patients scheduled to receive chemotherapy containing either of the four drugs (cisplatin, doxorubicin, epirubicin or oxaliplatin) were enrolled. They were randomized to receive intravenous ramosetron 0.3 mg plus dexamethasone 20 ...